Imperagen, a biotech startup focused on enzyme engineering, has successfully raised £5 million in a seed funding round led by PXN Ventures, with contributions from IQ Capital and Northern Gritstone. Founded in 2021 by scientists from the Manchester Institute of Biotechnology, the company aims to revolutionize the enzyme engineering process.
Transforming Enzyme Engineering: Imperagen seeks to streamline enzyme engineering, making it quicker, more efficient, and less expensive than traditional trial-and-error methods. The company employs a unique approach that leverages quantum physics-based simulations to predict enzyme behavior.
Core Technologies: The startup utilizes three main technologies:
- Quantum physics simulations to explore millions of enzyme mutations.
- Custom AI models tailored to specific enzyme challenges.
- Robotic automation for generating experimental data in a closed-loop simulation process.
These innovations aim to enhance the speed and reliability of enzyme development, which is critical in various industries, particularly pharmaceuticals.
Industry Impact: Enzymes play a vital role in drug development and are increasingly being explored for their potential to improve sustainability in sectors such as food production, biofuels, and agriculture. The advancements in enzyme engineering could significantly accelerate drug discovery and enhance the efficiency of industrial processes.
Leadership Changes: Guy Levy-Yurista has been appointed as the new CEO of Imperagen. With a background in AI and life sciences, he aims to advance the company's technology and expand its market presence. He noted that existing enzyme engineering processes often fall short at an industrial scale, and Imperagen's approach is designed to address these shortcomings.
Funding Utilization: The recent funding will support the hiring of AI specialists, bolster research and development efforts, and enhance the company’s experimental lab capabilities. Imperagen has raised a total of £8.5 million to date, and plans to build a robust go-to-market strategy over the next two years.
Future Aspirations: Imperagen envisions that the broader adoption of engineered enzymes will lead to cleaner, safer, and more sustainable products, benefiting both industries and the environment.
